APA (7th ed.) Citation

Fisher, S. S., Lindaas, A., Muthuri, S. G., Lloyd, P. C., Gruber, J. F., Richey, M. M., . . . Chillarige, Y. (2025). Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States. PLoS ONE, 20(11), 1. https://doi.org/10.1371/journal.pone.0333704

Chicago Style (17th ed.) Citation

Fisher, Shelby S., et al. "Risk of Neurologic or Immune-mediated Adverse Events After COVID-19 Diagnosis in the United States." PLoS ONE 20, no. 11 (2025): 1. https://doi.org/10.1371/journal.pone.0333704.

MLA (9th ed.) Citation

Fisher, Shelby S., et al. "Risk of Neurologic or Immune-mediated Adverse Events After COVID-19 Diagnosis in the United States." PLoS ONE, vol. 20, no. 11, 2025, p. 1, https://doi.org/10.1371/journal.pone.0333704.